An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis

Saved in:
Bibliographic Details
Published in:European urology 2019-01, Vol.75 (1), p.201-203
Main Authors: Necchi, Andrea, Giannatempo, Patrizia, Raggi, Daniele, Mariani, Luigi, Colecchia, Maurizio, Farè, Elena, Monopoli, Francesco, Calareso, Giuseppina, Ali, Siraj M., Ross, Jeffrey S., Chung, Jon H., Salvioni, Roberto
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal - therapeutic use
Antineoplastic Agents - therapeutic use
Humans
Lung Neoplasms - drug therapy
Lung Neoplasms - secondary
Male
Neoplasms, Germ Cell and Embryonal - drug therapy
Seminoma - drug therapy
Seminoma - secondary
Testicular Neoplasms - drug therapy
Testicular Neoplasms - pathology
Treatment Failure
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0302-2838
1873-7560
DOI:10.1016/j.eururo.2018.09.010